The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes.

Abstract

GLP-1 analogues have been proven to be effective in the treatment of type 2 diabetes mellitus. They stimulate insulin production and secretion, and suppress glucagon secretion, depending on the blood glucose level. They also have an effect on the brain, enhancing satiety, and on the gut, where they delay gastric emptying. Theoretically, in type 2 diabetes mellitus patients, the combination of a GLP-1 analogue with insulin seems attractive, because of the weight loss perceived in users of GLP-1 analogues in contrast to the weight gain seen in most patients starting insulin therapy, leading to even more insulin resistance. There are only a few randomised controlled trials which have studied this combination and several uncontrolled studies, which will be reviewed here.

• Authors: M M van der Klauw, B H R Wolffenbuttel
• Journal: The Netherlands journal of medicine (Neth J Med) Vol. 70 Issue 10 Pg. 436-43 (Dec 2012) ISSN: 1872-9061 [Electronic] Netherlands
• PMID: 23230012 (Publication Type: Journal Article, Review)

Chemical References

• Blood Glucose
• Insulin
• Glucagon-Like Peptide 1
• Glucagon

Topics

• Blood Glucose (drug effects, metabolism)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Drug Therapy, Combination
• Glucagon (antagonists & inhibitors, metabolism)
• Glucagon-Like Peptide 1 (analogs & derivatives)
• Humans
• Insulin (administration & dosage)
• Insulin Resistance
• Treatment Outcome